FIG. 1.

Schematic representation of CMRI vaccine priming and booster dose study design. Twenty healthy volunteers with no evidence of exposure to C. burnetii were inoculated with 0.3, 3.0, 15, 30, or 60 μg of CMRI and boosted according to the schedule shown. Blood was drawn for serologic and cellular immune response assays on the days indicated. Numbers signify the day or range of days (d) on which blood was drawn or booster immunization was given and are relative to the primary vaccination (d0).